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Objective: Randomized controlled trials have shown that growth hormone (GH) therapy has effects 
on growth, metabolism, and body composition. GH therapy is prescribed for children with growth 
failure and adults with GH deficiency. Carefully conducted observational study of GH treatment 
affords the opportunity to assess long-term treatment outcomes and the clinical factors and variables 
affecting those outcomes, in patients receiving GH therapy in routine clinical practice.
Design: The NordiNet® International Outcome Study (IOS) and the American Norditropin® 
Studies: Web Enabled Research (ANSWER Program®) are two complementary, 
non-interventional, observational studies that adhere to current guidelines for pharmacoepi-
demiological data.
Patients: The studies include pediatric and adult patients receiving Norditropin®, as prescribed 
by their physicians.
Measurements: The studies gather long-term data on the safety and effectiveness of real-
life treatment with the recombinant human GH, Norditropin®. We describe the origins, aims, 
objectives, and design methodology of the studies, as well as their governance and validity, 
strengths, and limitations.
Conclusion: The NordiNet® IOS and ANSWER Program® studies will provide valid insights 
into the effectiveness and safety of GH treatment across a diverse and large patient population 
treated in accordance with real-world clinical practice and following the Good Pharmacoepide-
miological Practice and STrengthening the Reporting of OBservational studies in Epidemiology 
(STROBE) guidelines.
Keywords: growth hormone replacement therapy, treatment outcome,  pharmacoepidemiology, 
survey
Introduction
Observational studies are valuable for assessing and charting the real-life management 
of patients and offer information to complement data from randomized, controlled trials 
(RCTs).1,2 RCTs are the recognized principal means of providing high-level evidence 
on the efficacy and safety of a therapeutic intervention. However, their results may 
have limited applicability or validity in routine clinical practice, where the patients 
encountered and the practices adopted in real-world disease management can differ 
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greatly from those considered and allowed within the protocol 
of a controlled trial setting3 (in which, for example, rare and 
atypical subgroups are excluded). Non-interventional, obser-
vational studies can therefore provide synergistic insights into 
the utilization and the effectiveness of treatments and allow 
for the evaluation and follow-up of numerous end points 
and parameters, including those unrelated to a treatment 
intervention, yet important to disease understanding. They 
also permit long-term follow-up of large numbers of patients 
who are prescribed chronic medication according to standard 
clinical practices. Moreover, for all prescribed therapies, the 
collection of postmarketing data is critical for the evaluation 
and characterization of the real-life effect and risk profile of 
treatments and can help in the detection of rare side effects 
and treatment interactions.4 Thus, balanced assessments of 
therapeutic interventions should draw on a variety of types 
of research5 and, within the mix, observational studies can 
serve a range of purposes – confirming or refuting previous 
findings, discovering new aspects of disease, and exploring 
and generating hypotheses for further investigation.3
One therapy area in which observational data in particu-
lar can provide valuable evidence and insights is the use of 
growth hormone (GH) to manage a host of conditions associ-
ated with GH deficiency (GHD) or in which normal growth 
is perturbed.6–9 In this therapy area, there is an established 
precedent of assessing the response to and safety of long-term 
treatment with GH and of supporting and complementing the 
clinical trial evidence base through registry tools.10
GH has multiple physiological actions, including the 
promotion of linear growth in childhood, and is essential 
for the maintenance of normal body composition throughout 
life.6,11,12 GH therapy may be used in childhood, to promote 
growth in children with GHD and in children with conditions 
characterized by insufficient growth, and also has a role in 
the management of adults with GHD. It follows that patients 
treated with GH, therefore, represent a highly heterogeneous 
group in terms of age range and clinical characteristics. GH 
treatment has been used in children for more than 50 years 
and in adults for over 20 years, and therapy is typically given 
long term.11 Many patients receiving GH therapy are enrolled 
in observational studies that are designed specifically for the 
brand of GH treatment they are receiving.10 These databases 
and observational studies have considerably extended the 
knowledge of GHD and its treatment, but many issues remain 
unresolved.
Norditropin® (somatropin [rDNA origin] injection) (Novo 
Nordisk A/S, Bagsværd, Denmark) is a recombinant human 
GH used as replacement therapy in patients with GHD or 
as pharmacological treatment for a number of conditions 
characterized by insufficient growth.13–16
This paper describes two complementary, large-scale, 
non-interventional, observational studies, the NordiNet® 
International Outcome Study (IOS) (NCT00960128)17 and 
the American Norditropin® Studies: Web Enabled Research 
(ANSWER Program®) (NCT00615953),18 that use the same 
electronic platform (NordiNet®/NovoNet®) for data manage-
ment and that have similar aims; namely, to gather long-term 
data on the effectiveness and safety of Norditropin® treatment 
in the usual clinical setting and to provide insight into the 
diseases of the specific endocrine patient populations man-
aged with GH therapy. In this paper we present the origins, 
objectives, methodology, and governance of these studies, 
followed by a discussion of their validity, strengths, and 
limitations, and ongoing and future uses for these two specific 
observational studies.
Methods
History
The NordiNet® IOS and ANSWER Program® are comple-
mentary international non-interventional registry studies 
monitoring the long-term effectiveness and safety of GH 
replacement therapy, specifically  Norditropin®, in routine 
clinical practice. Patients are entered into one or the other 
study, depending on location of the treating clinic. The 
NordiNet® IOS registry was launched in 2006 and currently 
aims to recruit to a planned sample size of 17,000 patients 
over a 10-year period. Prior to 2006, the national German 
Novo Nordisk non-interventional studies on Norditropin®-
treated patients, GrowthWin and NordiWin, initiated in 2001 
and 2003, respectively, captured data on the long-term safety 
and efficacy of Norditropin® in children and adults. The data 
from these two studies have been migrated into NordiNet® 
IOS.19,20 The ANSWER Program® is an observational, non-
interventional study that was launched in 2002 and includes, 
in addition, the follow up of some subjects from two 2-year 
RCTs assessing Norditropin® in children with GHD or 
growth failure. The ANSWER Program® plans to recruit 
approximately 18,000 patients and includes both pediatric 
and adult patients treated with Norditropin®.
Aims and objectives
The aims and objectives of NordiNet® IOS and the 
ANSWER Program® are to assess the clinical outcomes 
of real-life treatment of pediatric and adult patients with 
Norditropin®, as prescribed by treating physicians accord-
ing to standard clinical practice. The studies are gathering 
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long-term data on the effectiveness of treatment and follow 
short-term and long-term safety in children and adults treated 
with Norditropin®. They offer insights into the contemporary 
treatment of specific endocrine patient populations, with 
respect to demographic, disease, and patient characteristics 
such as country, age, sex, pubertal status, and diagnoses. The 
long-term and prospective nature of the studies allows for 
the analysis of longitudinal data with regard to outcomes and 
for the possibility of benchmarking and time-trend assess-
ments to evaluate the quality of treatment, adjusted for 
baseline data.
While the NordiNet® IOS and the ANSWER Program® 
have separate protocols, these are of similar design, with 
similar objectives and methods, and both are web-based 
studies sharing the same electronic platform (NordiNet®/
NovoNet®) for data management. This will allow for the 
combination of data if required, according to specific ques-
tions from researchers, authorities, and other pertinent 
stakeholders.
The overall effectiveness objectives of these studies in 
children are to investigate the short- and long-term effects 
of Norditropin® on linear growth and to identify factors that 
modify linear growth in children treated with Norditropin®. 
One major goal is to determine the predictive value of base-
line parameters such as age, bone age, sex, and diagnostic 
indication, and of pretreatment peak GH and insulin-like 
growth factor 1 (IGF-I) levels, on treatment outcomes. The 
studies are also investigating the effect of treatment in pediat-
ric patients, on body proportion and metabolic parameters.
Both studies have the objective of studying GH-deficient 
patients in transition, specifically investigating the effects of 
stopping Norditropin® treatment in pediatric GHD patients 
who have reached their adult height and the clinical impact 
of reinitiating treatment on somatic development in these 
patients.
In adults, the studies are investigating the short- and long-
term effects of Norditropin® treatment on body composition 
and metabolic parameters, and seek to identify factors that 
modify those parameters.
In both pediatric and adult patients, the safety of 
 Norditropin® is being assessed using physician reports 
in the databases, of adverse events (AEs), adverse drug 
reactions (ADRs), medical events of special interest, and 
pregnancies. If an investigator assesses an AE/ADR as 
serious (SAE/SADR), he/she is instructed to complete 
and “sign” an  electronic SAE/SADR form, to send the 
information related to this event to the database within 
24 hours. The investigator is further instructed to inform the 
local authority about the SAE/SADR, in accordance with 
country-specific rules.
Governance of the databases and studies
Data analyses and publication of the combined results from 
NordiNet® IOS and the ANSWER Program® are governed by 
an international study committee (ISC). The ISC comprises 
elected chairpersons drawn from the pediatric and adult 
clinical endocrinological specialties, each acting as a national 
clinical representative of a country involved in the IOS and 
reporting data on at least 100 patients (maximum two repre-
sentatives per country), and a maximum of five persons from 
Novo Nordisk. The ISC meets annually, with the power to call 
additional special meetings and to form working groups. The 
NordiNet® ISC acts as the custodian of the database and as the 
ultimate decision-making body concerning the presentation 
and publication of international data from the studies.
Data access, analyses, and reporting are managed under 
the guidance of Novo Nordisk, the owners of the data 
 collected. The studies are conducted in accordance with the 
Declaration of Helsinki; for both studies, patients provide 
written, informed consent for data collection. All data in 
NordiNet® IOS and the NovoNet® ANSWER Program® are 
made anonymous. At the individual center level, approval 
of the local ethics committee or institutional review board 
is a prerequisite for enrollment into NordiNet® IOS and the 
NovoNet® ANSWER Program®, in accordance with country-
specific rules.
validity of NordiNet® IOS and ANSWER Program® 
as observational studies
Both NordiNet® IOS and ANSWER Program® are guided by 
the Good Pharmacoepidemiological Practice guidelines on 
the design and reporting of observational studies, as defined 
by the International Society for Pharmacoepidemiology,  and 
the STrengthening the Reporting of OBservational studies 
in Epidemiology (STROBE) guidelines.3,21 Both studies 
have a written protocol describing the proposed study tasks, 
milestones and timelines, objectives, and rationale, with 
full descriptions of the research methods, study conduct, 
responsibilities of personnel and facilities, resource com-
mitment, communication and archiving plans for data, and 
the processes for AE reporting.
Study designs, data sources, and data flow
There are 20 countries participating in the two studies: 19 in 
NordiNet® IOS (Czech Republic, Denmark, Finland, France, 
Germany, Hungary, Ireland, Israel, Italy, Lithuania, The 
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Netherlands, Norway, Russia, Serbia, Montenegro, Slovenia, 
Sweden, Switzerland, UK); and the US in the ANSWER 
Program®.
Those eligible for inclusion in the studies are pediatric 
and adult patients who are already on Norditropin® treatment 
or who are starting on Norditropin® treatment. This includes 
patients in the following pediatric diagnosis groups: children 
with growth failure or short stature due to GHD (either as an 
isolated occurrence or as part of multiple pituitary hormone 
deficiency), small for gestational age (SGA), Turner syndrome, 
Prader–Willi syndrome, Noonan syndrome (NS), and chronic 
renal disease; adult patients with GHD; and GHD patients dur-
ing transition. This latter group includes GHD patients treated 
with Norditropin® during childhood who achieved adult height 
and were off treatment for up to a maximum of 2 years before 
reassessment of GH status and reconfirmation of GHD. In terms 
of clinical diagnoses, the studies collect data based on inves-
tigators’ diagnosis and encourage the use of the International 
Classification of Diseases 10th Revision (ICD-10) criteria as 
the routine tool for categorization of diagnoses.22
The study databases use the same electronic, web-based 
platform (NordiNet®/NovoNet®) for electronic data capture in 
the study case report forms (CRFs), which provide automatic 
data validation at data entry. The data entered into the plat-
forms are specified in the NordiNet®/NovoNet® CRFs, with 
certain adjustments and/or additions allowed at the investi-
gator’s discretion. All the physician investigators are trained 
in using the web-based application, and the data on the host 
server are protected by an individual user ID and password. 
The patient ID remains with a patient even if he or she moves 
or changes practitioner. This method of assigned patient ID 
ensures that patients can be followed long term and through 
transition. The electronic signature enables the investigator to 
export the data to the central registry database, in accordance 
with the NordiNet® IOS and ANSWER Program® protocols; 
the data captured therein constitute the NordiNet® IOS and 
ANSWER Program® data sets, respectively.
The central registry database is run and supported by 
Novo Nordisk. All physicians reporting patient data into the 
database in accordance with agreements specified by Novo 
Nordisk are considered to be NordiNet® IOS or ANSWER 
Program® members and investigators.
All patient data reported into the central database are man-
aged by the Clinical Data Management Department, Novo 
Nordisk Inc (for ANSWER Program®) and the Novo Nordisk 
Epidemiology Department in Denmark (for NordiNet® IOS). 
Data managers follow up on data flow and prepare periodic 
reports to ensure the completeness and correctness of data.
Patient histories and physical examination data are 
prospectively or retrospectively entered by the participating 
physician investigators, using the web-based CRFs. The 
study protocols specify the examination parameters required 
at baseline and follow-up visits for both pediatric and adult 
patients (Tables 1 and 2). Physician investigators are encour-
aged to enter data as soon as possible after clinic visits. At the 
baseline visit, the following CRF materials are completed: 
registration form (for enrollment in the ANSWER Program®), 
diagnosis form, background form, history of examinations/
treatments form, baseline form, and menarche form (if 
appropriate). Once a pediatric GHD patient has reached adult 
height and GH treatment is discontinued, the patient may 
continue to be followed up during a transition period for up 
to 2 years (the patient will be asked to sign a separate transi-
tion informed consent for this). If, at that time, reassessment 
of the patient’s GHD diagnostic criteria indicates that the 
patient satisfies the diagnostic criteria of adult GHD and the 
patient would like to reinitiate GH treatment, the physician 
will initiate treatment in the pediatric module but eventually 
transfer the patient to an adult endocrinologist using the adult 
module, with all information obtained before reinitiation of 
GH treatment considered as the baseline information for adult 
treatment. At follow-up visits, there is a dedicated follow-up 
form; additional forms are used to collect data on AEs, preg-
nancy, menarche, consent for off-treatment data collection, 
diagnosis, change of clinic, and an end-of-registration form 
(for subjects leaving the registry).
Study variables
Study data include all relevant demographic and clinical 
characteristics of the enrolled adult and pediatric patients, 
the dose of Norditropin® and any dose adjustments made 
during the course of patient treatment, clinical outcomes, and 
quality-of-life measurements. The study protocols provide 
clear guidance concerning the data to be captured (Tables 1 
and 2); however, data collection is ultimately conducted in 
accordance with the routine clinical practice of the center 
and investigator.
The effectiveness end points assessed in children include 
the effect of Norditropin® on height gain and body weight, 
blood biochemistry (including IGF-I, and pituitary and other 
hormones, as relevant) and bone age. Uniquely, in NordiNet® 
IOS only, there is an option for automatic assessment of 
bone age in children, by use of a validated software called 
BoneXpert® (Visiana, Holte, Denmark).23
In adult patients, assessed effectiveness end points include 
the effect of Norditropin® on body weight and composition, 
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Table 1 Pediatric indications: baseline and follow-up visit 
examination parameters evaluated across the NordiNet® IOS and 
ANSWER® Program studies
Examination  
parametera
Baseline  
visit
Follow- 
up visits
Follow-up  
in transition  
(only GHD)
Last 
visit
Patient ID X
Date of visit X X X X
Demographic data/background 
information
Date of birth X
Sex X
Patient consent X
Patient consent date X
Patient consent for off- 
treatment data collection,  
consent date (separate  
study form)
X
Diagnoses X (X) (X) (X)
Date of diagnoses X (X) (X) (X)
Gestational age X
Birth weight X
Birth length X
Birth head circumference X
Pregnancy  
information (SGA)
X
Apgar score (SGA) X
Mother’s measured  
(or reported) height
X
Father’s measured  
(or reported) height
X
Medical history  
(TS, NS, GHD)
X
Treatment history  
(GHD, oncology  
treatment, radiotherapy,  
chemotherapy)
X
Phenotype (TS) X
History of examinations X
Auxology
Height X X X (X)
Weight X X X X
Sitting height X X (X)
Arm span X X (X)
Hip circumference (X) (X) X X
Triceps skin fold X X X X
Upper arm  
circumference
X X X X
Sexual maturation
Breast (Tanner) female X X (X) (X)
Pubic hair (Tanner)  
(female and male)
X X (X) (X)
Genitalia (Tanner) (male) X X (X) (X)
Left testis (male) X X (X) (X)
Right testis (male) X X (X) (X)
Menarche (if occurred) X X (X) (X)
Pregnancy X X X
Vital signs
Pulse X X X X
(Continued)
Table 1 (Continued)
Examination  
parametera
Baseline  
visit
Follow- 
up visits
Follow-up  
in transition  
(only GHD)
Last 
visit
Systolic and diastolic BP X X X X
Quality of life  
questionnaire
X X X X
Imaging
Bone age X X (X)
Cranial imaging (GHD) X X (X)
DEXA X (X)
BIA X (X)
Cardiac ultrasound/ 
imaging (TS, NS)
X X X
Hearing (TS)
GH test (date, type,  
GH peak)
X X
Biochemistry
IGF-1 X X X X
IGF-1 – SDS X X X X
IGFBP-3 X X X X
HbA1c X X X X
Thyroid function  
(TSH, free T4)
X X X X
Fasting blood glucose X X X X
Fasting insulin X X X (X)
LDL X X X X
HDL X X X X
Triglycerides X X X X
Total cholesterol X X X X
FSH, LH (TS) X X X
Additional biochemistry (CRD)
Hemoglobin X X X
Magnesium X X X
Potassium X X X
Calcium X X X
Phosphate X X X
Serum albumin X X X
Serum creatinine X X X
Serum urea X X X
Estimated creatinine  
clearance
X X X
Cystatin C X X X
Serum nitrogen X X X
Estimated glomerular  
filtration rate
X X X
Alkaline phosphatase  
(AP)
X X X
Fibroblast growth  
factor 23
X X X
Ostase  
(bone-specific AP)
X X X
Serum bicarbonate X X X
25-hydroxy-vitamin D X X X
Parathyroid hormone X X X
Deoxypyridinoline X X X
Protein in urine X X X
Creatinine in urine X X X
(Continued)
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Table 1 (Continued)
Examination  
parametera
Baseline  
visit
Follow- 
up visits
Follow-up  
in transition  
(only GHD)
Last 
visit
Dialysis (CRD) X X X
GH treatment
Date for start  
of GH treatment
X
GH dose X X (X) (X)
GH treatment  
reinitiation
X
Number of missed  
injections since last visit
X (X) X
Change of GH  
treatment
X (X) (X)
Concomitant medicationX X X (X)
AEs (details AE study 
form)
X X X
End of GH treatment (X)
Clinic change X
Date of end of  
registration in study
X
Notes: The ANSWER® Program does not include BoneXpert® (visiana, Holte, 
Denmark) evaluations. aThe only evaluated parameters are those that are a part of 
routine practice, in accordance with local requirements. (X) signifies “if relevant.”
Abbreviations: AE, adverse event; ANSWER, American Norditropin® Studies: 
Web Enabled Research; AP, alkaline phosphatase; BIA, bioelectrical impedance 
analysis; BP, blood pressure; CRD, chronic renal disease; DEXA, dual-energy 
X-ray absorptiometry; Free T4, free thyroxin; FSH, follicle stimulating hormone; 
GH, growth hormone; GHD, growth hormone deficiency; HbA1c, hemoglobin A1c; 
HDL, high-density lipoprotein; IGF-1, insulin-like growth factor 1; IGFBP-3, insulin-
like growth factor binding protein-3; IOS, International Outcome Study; LDL, low-
density lipoprotein; LH, luteinizing hormone; NS, Noonan syndrome; SDS, standard 
deviation score; SGA, small for gestational age; TS, Turner syndrome; TSH, thyroid 
stimulating hormone.
Table 2 Adult indications: baseline and follow-up visit examination 
parameters evaluated across the NordiNet® IOS and ANSWER® 
Program studies
Examination parametera Baseline  
visit
Follow-up  
visits
Last 
visit
Patient ID X
Date of visit X X X
Date of birth X
Demographic data/ 
background information
Sex X
Patient consent X
Patient consent date X (X) (X)
Diagnoses X (X) (X)
Date of diagnoses X (X) (X)
Medical history (diabetes, tumors,  
malignant disease, subarachnoid  
hemorrhage, traumatic brain injury)
X
Radiotherapy X
Chemotherapy X
Surgery
Physical examination and vital 
signs
Height X
Weight X X X
Waist circumference X X X
Hip circumference X X X
Upper-arm circumference X X X
Skinfold triceps X X X
Systolic BP X X X
Diastolic BP X X X
Pulse X X X
Smoking X X X
Pituitary imaging X
DEXA X X X
Bioimpedance X X X
Biochemistry
GH test (date, type, GH peak) X
IGF-I X X X
IGF-I – SDS X X X
IGFBP-3 X X X
HbA1c X X X
Fasting blood glucose X X X
Fasting insulin X X X
Thyroid function (TSH, free T4) X X X
Total cholesterol X X X
HDL X X X
LDL X X X
QoL X X X
GH treatment X X
Date for start of GH treatment X
GH dose X X
Treatment change X X
Concomitant medication X X X
AE description  
(details AE study form)
X X
Pregnancy X X
Number of missed injections  
since last visit
X X
End of GH treatment X
quality of life, blood chemistry (including IGF-I, pituitary 
hormones and sex hormones routinely, and thyroid and 
adrenal hormones if necessary).
All data are collected in accordance with routine medical 
practice and country-specific rules, and the CRFs allow for 
effectiveness end points to be adapted and edited according 
to local situations and practices.
Safety outcomes
The overall safety objectives follow short- and long-term 
safety in children and adults treated with Norditropin®. 
At every visit, the investigators ascertain the occur-
rence of AEs and SAEs, regardless of their relation to 
treatment, medical events of special interest (eg, wrong 
drug administration), and pregnancies. The investigator 
reports information related to SAEs and medical events 
of special interest within 24 hours of obtaining knowledge 
of the event; pregnancy exposures are reported within 
14 calendar days. Nonserious AEs that are not attributed 
to treatment are not registered.
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(Continued)
Table 2 (Continued)
Examination parametera Baseline  
visit
Follow-up  
visits
Last 
visit
Clinic change X
Date of end of registration in study X
Notes: The ANSWER® Program does not include BoneXpert® (visiana, Holte, 
Denmark) evaluations. aThe only evaluated parameters are those that are a part of 
routine practice, in accordance with local requirements. (X) signifies “if relevant.”
Abbreviations: AE, adverse event; ANSWER, American Norditropin® Studies: Web 
Enabled Research; BP, blood pressure; DEXA, dual energy X-ray absorptiometry; 
GH, growth hormone; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; IGF-I, 
insulin-like growth factor-I; IGFBP-3, insulin-like growth factor binding protein-3; 
IOS, International Outcome Study; LDL, low-density lipoprotein; SDS, standard 
deviation score; TSH, thyroid stimulating hormone; QoL, quality of life.
Data analyses and communication
Statistical analyses of study data will be described per analy-
sis and per publication of the study analyses. Novo Nordisk is 
committed to communicating, or otherwise making available 
for public examination, the results of these studies, regardless 
of the outcomes. Study results, which are reviewed regularly 
under the governance of the ISC or by investigators and 
internal study personnel in the ANSWER Program®, are 
presented on a regular basis at major scientific meetings and 
published in relevant peer-reviewed journals.
Current data size
As of July 1, 2012, NordiNet® IOS had enrolled 11,370 
pediatric patients (GHD: 6716; SGA: 2642; Turner syndrome: 
999; idiopathic short stature: 99; NS: 104; Prader–Willi syn-
drome: 85; and other: 567) and 1837 adult patients (GHD: 
1528 and other: 309).
As of September 25, 2012, the NovoNet® ANSWER 
Program® had enrolled 13,681 pediatric patients (GHD: 
7180; SGA: 1024; Turner syndrome: 718; idiopathic short 
stature: 1452, NS: 184; Prader–Willi syndrome: 120; and 
other: 2334) and 468 adult patients (GHD: 214 and multiple 
pituitary hormone deficiency: 254).
Discussion
The NordiNet® IOS and the NovoNet® ANSWER Program® 
studies are similarly designed observational studies that 
capture data, via a web-based platform, describing an inter-
national, multicenter cohort of patients receiving Norditro-
pin® in routine clinical practice. The primary value of the 
NordiNet® IOS and NovoNet® ANSWER Program® obser-
vational studies is to provide real-world data on the clinical 
effectiveness and safety experience of Norditropin® therapy in 
children, adolescents, and adults, with a special focus on the 
transition phase. Data from these observational studies will 
also help to increase understanding of the patient populations 
and disease areas under study and provide a valid model for 
studying treatment effects. The common design allows for the 
IOS and ANSWER Program® data to be pooled, providing a 
greater number of cases to investigate patient subgroups and 
infrequent events, and strengthening the statistical power of 
the data. Specific to the NordiNet® IOS study, is the possibil-
ity of automatically assessing the bone age in children, and 
to both studies, the ongoing collection of normative data on 
body composition and IGF-I, in adults.
These international, prospective studies support 
research efforts within the field of GH therapy and the 
design and potential for collation of study data, and stimu-
late international cooperation among pediatric and adult 
endocrinologists. As described in this paper, the NordiNet® 
IOS and NovoNet® ANSWER Program® studies are not 
constrained by the strict and highly specific nature of a trial 
protocol and, therefore, offer an inclusive picture of the use 
and effectiveness of Norditropin® in clinical practice as well 
as allowing specific subgroups of patients receiving GH to be 
followed and assessed. The protocol of the studies attempts 
to capture numerous end points and informative parameters, 
including those unrelated to traditional GH treatment end 
points. The design of the studies and their CRFs allow flex-
ibility not possible within an RCT, permitting investigators 
to add additional data and to suggest additional parameters 
and reporting according to their current clinical practices 
and observations.
The importance of the databases is reflected in the articles 
that have already published data from NordiNet® IOS and 
the NovoNet ANSWER Program®.24–26 One of these, from the 
NovoNet ANSWER Program®, sought to identify potential 
predictors of good response to GH, in children with short 
stature of various etiologies;24 a second, using data from 
both studies, focused on comparing 2-year treatment out-
comes between patients from different diagnostic subgroups 
(idiopathic GHD, SGA, idiopathic short stature, or multiple 
pituitary hormone deficiency),26 while a third focused exclu-
sively on patients with NS.25 Other publications have reported 
on the effects of sex, age, and pubertal status on outcome of 
GH treatment in children.27–29
In addition to offering data on long-term treatment effec-
tiveness and a means to easily discover interactions with 
other treatments, a unique feature of the NordiNet® IOS and 
NovoNet® ANSWER Program® studies is their intentionally 
designed capacity to observe and follow pediatric patients 
during the transition from childhood to adulthood. It is hoped 
that the studies will provide much needed data on the out-
comes of children with GHD, treated with GH in childhood 
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until adult height is reached, and the effects of treatment 
discontinuation and of reinitiation in cases of severe GHD 
that persists into adulthood.
Cost-effectiveness data, increasingly required by pre-
scribers and authorities, can be derived from the databases, 
which offer current data on GH treatment outcomes across a 
heterogeneous patient population. These studies also include 
the assessment of bone age performed by the treating clini-
cian, which may be useful in the routine care of pediatric 
patients. Collection of data on body composition, using, for 
example, bioimpedance analysis, and comparison of this 
data with normative data for adult patients with GHD could 
also be of great value.
The size of the cohorts studied by NordiNet® IOS and the 
NovoNet® ANSWER Program® allows the generation of a 
large collective data set that can be interrogated and analyzed 
by specific patient subgroups and according to key epide-
miological and treatment questions. This means that these 
studies will offer insights and data on large patient popula-
tions (internationally and nationally), while also having the 
depth and flexibility to allow study of particular subsets of 
patients within those populations.
There are a number of notable strengths of the  NordiNet® 
IOS and NovoNet® ANSWER Program® observational 
 studies. The studies collect retrospective data, yet are pro-
spective in design, aiding prompt recognition of effects and 
associations, and the patient populations of the studies reflect 
and provide a means of surveillance of the diverse patient 
groups given Norditropin® in clinical practice, groups which 
together constitute a large number of patients exposed to 
Norditropin® treatment over a protracted time period. The 
validity of these studies is enhanced by their strict adherence 
to contemporary guidelines on the principles and conduct 
of non-interventional, observational studies, such as those 
outlined in STROBE and by the Good Pharmacoepide-
miological Practice guidelines.3,21 The software tools used 
in these studies provide a secure, sophisticated, and reactive 
database.  Independent governance of the studies is assured 
by an expert and diverse body of counselors, the ISC, which 
acts as custodian of the data and advises on all aspects of data 
communication, and on publication of the data, regardless of 
outcomes, to the medical community.
Potential limitations of the NordiNet® IOS and  NovoNet® 
ANSWER Program® studies are those common to any obser-
vational registry and include the uncontrolled nature of the 
study and of data collection, and the potential selection bias 
due to enrollment of selected clinics. Potential bias can also be 
caused by the systematic error introduced with use of different 
laboratory assays in different clinics. The lack of central labora-
tory analysis limits the interpretation of relevant blood analyses, 
especially IGF-I. There is also a risk for information bias due 
to incomplete reporting, poor quality, or erroneous informa-
tion recording regarding treatment exposure and treatment 
outcomes, or due to investigators failing to report confounding 
factors, misclassifying a diagnosis, or failing to report data 
accurately. The automated data validation system attempts to 
mitigate against these aspects of information recording.
The heterogeneous nature of the patient population is 
both a limitation and strength of the studies. Both stud-
ies permit and support local treatment practices; however, 
centers providing data may have very different access to the 
use of technologies. Confounders such as these should be 
included in the analyses and reported accordingly. There is 
also a continuing need to obtain long-term outcome data on 
transition patients into adulthood.
In conclusion, the NordiNet® IOS and NovoNet® 
ANSWER Program® studies will provide valid and important 
insights into the effectiveness and safety of GH treatment 
across a diverse and large patient population that is treated 
in accordance with real-world clinical practice, by following 
the Good Pharmacoepidemiological Practice guidelines and 
STROBE guidance on the conduct of observational studies. 
The studies include an easily performed assessment of bone 
age and the possibility of calculating cost-effectiveness and 
will offer unique insights into the management of GHD 
patients through transition.
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